Japan Regenerative Medicine
Japanese regenerative medicine company dedicated to developing and commercializing innovative treatments for heart diseases, especially targeting pediatric congenital heart defects. Their mission is to become a leading company in regenerative medicine for heart conditions, utilizing cardiac stem cells to create new therapeutic products. They aim to deliver advanced regenerative therapies to patients and improve their quality of life, with a focus on practical application of cutting-edge research.
Industries
Nr. of Employees
small (1-50)
Products
Autologous cardiac stem cell human cell-processed product (clinical candidate)
A human cell-processed therapeutic product derived from a patient's own cardiac-resident stem cells, developed for treatment of severe pediatric congenital heart disease and end-stage pediatric heart failure.
Autologous cardiac stem cell human cell-processed product (clinical candidate)
A human cell-processed therapeutic product derived from a patient's own cardiac-resident stem cells, developed for treatment of severe pediatric congenital heart disease and end-stage pediatric heart failure.
Services
End-to-end clinical development support including trial initiation, conduct, and long-term patient follow-up for cell-processed products.
Provision of exclusive licensing arrangements for patented academic stem cell technologies and execution of manufacturing technology transfer to enable production of human cell-processed products.
Design and execution of GLP-compliant nonclinical safety studies and preclinical efficacy assessments in relevant animal models to support regulatory submissions.
End-to-end clinical development support including trial initiation, conduct, and long-term patient follow-up for cell-processed products.
Provision of exclusive licensing arrangements for patented academic stem cell technologies and execution of manufacturing technology transfer to enable production of human cell-processed products.
Design and execution of GLP-compliant nonclinical safety studies and preclinical efficacy assessments in relevant animal models to support regulatory submissions.
Expertise Areas
- Cardiac regenerative medicine
- Pediatric congenital heart disease therapeutics
- Autologous cell therapy development
- Clinical trial management for cell therapies
Key Technologies
- Cardiac stem cell therapy
- Autologous human cell-processed products
- Cell therapy manufacturing and process transfer
- GLP-compliant preclinical testing